<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432017000500625</article-id>
<article-id pub-id-type="doi">10.7399/fh.10787</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review]]></article-title>
<article-title xml:lang="es"><![CDATA[Revisión de la estabilidad química del ondansetrón con otros medicamentos en mezclas de administración parenteral]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estan-Cerezo]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-Pulido]]></surname>
<given-names><![CDATA[Inmaculada]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Lucena]]></surname>
<given-names><![CDATA[Francisco José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Matoses-Chirivella]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soriano-Irigaray]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarro-Ruiz]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Universitario de Elche-FISABIO Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Alicante ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>41</volume>
<numero>5</numero>
<fpage>625</fpage>
<lpage>629</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432017000500625&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432017000500625&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432017000500625&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: This review was prepared to offer the most complete information about the use of ondansetron in parenteral admixtures with other drugs.  Method: The search was done from September 2016 to April 2017 by using electronic databases Stabilis® and Micromedex® solutions, Medline/PubMed and Scholar Google searching publications about ondansetron stability in parenteral infusion when is administered by itself or with other medication.  Results: 49 studies are included with a total of 53 drugs. 15 drugs were found compatible administered with ondansetron in a clinical routine concentration range in intravenous administration. Also, four ternary blends were found compatible and another one was incompatible. Otherwise, 38 drugs were found incompatible.  Conclusions: Compatibility of ondansetron offers a broad number of options to be used to avoid nausea and vomiting symptoms in patients with other concomitant medication.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Esta revisión ha sido preparada para recopilar toda la información referente a la estabilidad del ondansetrón en mezclas parenterales junto a otros fármacos.  Método: La búsqueda fue realizada entre septiembre de 2016 y abril de 2017 empleando bases de datos electrónicas como Stabilis® y Micromedex® solutions, Medline/PubMed y Google Académico buscando publicaciones sobre la estabilidad del ondansetrón para infusión vía parenteral cuando es administrado en monoterapia o en una mezcla con otros fármacos.  Resultados: En este trabajo han sido incluidos 49 artículos con un total de 53 fármacos. 15 fármacos han sido descritos como compatibles con ondansetrón en concentraciones habituales en la clínica práctica para administración intravenosa. Además, cuatro mezclas ternarias han sido descritas como compatibles y una como incompatible. Por otro lado, 38 fármacos han sido descritos como incompatibles para su administración con ondansetrón.  Conclusiones: La compatibilidad del ondansetrón ofrece un amplio rango de opciones para evitar los síntomas de náuseas y vómitos en pacientes con otra medicación concomitante.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Ondansetron]]></kwd>
<kwd lng="en"><![CDATA[Chemical stability]]></kwd>
<kwd lng="en"><![CDATA[Oncology]]></kwd>
<kwd lng="en"><![CDATA[Nausea]]></kwd>
<kwd lng="en"><![CDATA[Palliative medicine]]></kwd>
<kwd lng="es"><![CDATA[Ondansetrón]]></kwd>
<kwd lng="es"><![CDATA[Estabilidad]]></kwd>
<kwd lng="es"><![CDATA[Oncología]]></kwd>
<kwd lng="es"><![CDATA[Náusea]]></kwd>
<kwd lng="es"><![CDATA[Medicina paliativa]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín de Rosales-Cabrera AM]]></surname>
<given-names><![CDATA[López-Cabezas C]]></given-names>
</name>
<name>
<surname><![CDATA[García-Salom]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diseño de una matriz de riesgo para la valoración de los preparados estériles en los centros sanitarios]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2014</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>202-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liberati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tetzlaff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement]]></article-title>
<source><![CDATA[Open Med]]></source>
<year>2009</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casto]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron stored in polypropylene syringes]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1994</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>712-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosso]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Prince]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1992</year>
<volume>49</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2223-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blaise]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Vigneron]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Perrin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Noirez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of refrigerated and frozen solutions of ondansetron hydrochloride]]></article-title>
<source><![CDATA[Eur J Hosp Pharm]]></source>
<year>1994</year>
<volume>4</volume>
<page-range>12-3</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Dukes]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Kao]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Bertch]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hak]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron in largevolume parenteral solutions]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1992</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>768-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jhee]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Inagaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1993</year>
<volume>50</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1918-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leak]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Woodford]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical development of ondansetron injection]]></article-title>
<source><![CDATA[Eur J Cancer Clin Oncol]]></source>
<year>1989</year>
<volume>25</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S67-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stiles]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride in portable infusionpump reservoirs]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1992</year>
<volume>49</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1471-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[QA]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1995</year>
<volume>29</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1106-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2016</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1869-75</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[QA]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1994</year>
<volume>51</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2138-42</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altannak]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative LC-MS stability indicating assays of ondansetron hydrochloride/naloxone hydrochloride and metoclopramide hydrochloride/naloxone hydrochloride used in palliative care]]></article-title>
<source><![CDATA[Int J Pharm Pharm Sci]]></source>
<year>2015</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>109-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hagan]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Mallett]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1996</year>
<volume>53</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1431-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evrard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ceccato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspard]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Delattre]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Delporte]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1997</year>
<volume>54</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1065-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bougouin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thelcide]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Crespin-Maillard]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maillard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kinowski]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Favier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>2005</year>
<volume>62</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2001-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schaller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Placek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duersch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids]]></article-title>
<source><![CDATA[Cancer Chemother Pharmacol]]></source>
<year>2013</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>509-13</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Savage]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1995</year>
<volume>52</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>514-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Nazzar]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Leff]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1995</year>
<volume>52</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2570-3</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride and five antineoplasic medications]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1996</year>
<volume>53</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1297-300</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estan-Cerezo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Matoses-Chirivella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano-Irigaray]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Murcia-López]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Lucena]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro-Ruiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability and compatibility of ondansetron with haloperidol in parenteral admixtures]]></article-title>
<source><![CDATA[Eur J Hosp Pharm]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Narducci]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1993</year>
<numero>7</numero>
<issue>7</issue>
<page-range>1410-4</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Venkateshwaran]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Ponder]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1997</year>
<volume>54</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>915-20</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moya-Gil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Gómez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Gras-Colomer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Porta-Oltra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Climente-Martí]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability studies of ternary mixtures containing fosaprepitant, dexamethasone, ondansetron and granisetron used in clinical practice]]></article-title>
<source><![CDATA[J Anal Bioanal Tech]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>307</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Tramonte]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Grilley]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1991</year>
<volume>48</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>988-92</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1994</year>
<volume>51</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1792-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Saenz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
<name>
<surname><![CDATA[Ingram]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration]]></article-title>
<source><![CDATA[Int J Pharm Compound]]></source>
<year>2001</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>314-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of meropenem with commonly used injectable drugs]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>1996</year>
<volume>53</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2853-5</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trusley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kupiec]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of micafungin injection with other drugs during simulated Y-site co-administration]]></article-title>
<source><![CDATA[Int J Pharm Compound]]></source>
<year>2006</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>230-2</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Saenz]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ogundele]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Ingram]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2289-93</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Bready]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection]]></article-title>
<source><![CDATA[Am J Hosp Pharm]]></source>
<year>1992</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>402-6</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[BX]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2016</year>
<volume>95</volume>
<numero>25</numero>
<issue>25</issue>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ondansetron compatible with sodium acetate]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1993</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>197</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kupiec]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Gole]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jimidar]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Vermeersch]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1545-51</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="">
<source><![CDATA[Summary of product characteristics of Bridion]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="">
<source><![CDATA[Mesna and furosemide. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="">
<source><![CDATA[Azathioprine sodium. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="">
<source><![CDATA[Cefepime HCl. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="">
<source><![CDATA[Ondansetron HCl. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="">
<source><![CDATA[Pentobarbital sodium and phenobarbital sodium. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="">
<source><![CDATA[Pantoprazole sodium. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="">
<source><![CDATA[Ertapenem. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="">
<source><![CDATA[Dantrolene sodium. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="">
<source><![CDATA[Foscarnet sodium. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="">
<source><![CDATA[Chloramphenicol sodium succinate. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="">
<source><![CDATA[Cefamandole nafate. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="">
<source><![CDATA[Inamrinone lactate. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="">
<source><![CDATA[Indomethacin sodium. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="">
<source><![CDATA[Trastuzumab. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="">
<source><![CDATA[Rituximab. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="">
<source><![CDATA[Gemtuzumab. In: Micromedex Solutions (database on the Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
